Fimasartan
|
|
|
- CAS-Nr.
- 247257-48-3
- Englisch Name:
- Fimasartan
- Synonyma:
- Kanarb;BR-A-657;Fimasartan;Fimasartan D4;Unii-p58222188p;KANARB; BR-A-657;Fimasartan(BR-A-657);FiMasartan USP/EP/BP;Fimasartan Impurity H;2-(1-((2'-(2H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrim
- CBNumber:
- CB22128722
- Summenformel:
- C27H31N7OS
- Molgewicht:
- 501.65
- MOL-Datei:
- 247257-48-3.mol
|
Fimasartan Eigenschaften
- Schmelzpunkt:
- >155°C (dec.)
- Siedepunkt:
- 693.0±65.0 °C(Predicted)
- Dichte
- 1.25
- storage temp.
- 2-8°C
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 4.16±0.10(Predicted)
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Fimasartan Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name Kanarb by Boryung Pharmaceuticals.
Verwenden
Fimasartan is a new angiotensin II receptor blocker antagonist and also functions as an antihypertensive agent.
Biologische Aktivität
Fimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure.
Mechanism of action
Angiotensin II activates AR1 leading to vasoconstriction and increased noradrenaline release which further increases vasoconstriction via action at α1-adrenergic receptors. It also stimulates secretion of aldosterone which acts to increase sodium and water reabsorption in the renal tubules. Fimasartan bind to and antagonizes AR1 preventing vasoconstriction and reducing aldosterone secretion to increase natriuresis leading to a reduction in blood volume. Together these effects produce an anti-hypertensive effect.
Fimasartan Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Fimasartan Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 174)Lieferanten
247257-48-3()Verwandte Suche:
- 2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one
- Fimasartan
- Unii-p58222188p
- 2-(1-((2'-(2H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrim
- 2-(2-butyl-4-Methyl-6-oxo-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)-1,6-dihydropyriMidin-5-yl)-N,N-diMethylethanethioaMide
- 2-(2-butyl-4-Methyl-6-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methoxy)pyriMidin-5-yl)-N,N-diMethylacetaMide-yl)-N,N-diMethylacetaMide
- BR-A-657
- Kanarb
- 5-PyriMidineethanethioaMide,2-butyl-1,6-dihydro-N,N,4-triMethyl-6-oxo-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-
- Fimasartan(BR-A-657)
- 2-(1-((2'-(2H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide
- Fimasartan Impurity H
- KANARB; BR-A-657
- 2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide
- 2-(2-butyl-4-methyl-6-((2'-(1-trityl-1H-tetrazol-5-yl)-[ 1,1'-biphenyl]-4-yl)methoxy)pyrimidin-5-yl)-N,N- dimethylacetamide
- FiMasartan USP/EP/BP
- 2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one USP/EP/BP
- 2-(2-Butyl-4-methyl-6-oxo-1-{[2'-(1H-tetrazol-5-yl)- 4-biphenylyl]methyl}-1,6-dihydro-5-pyrimidinyl)-
N,N-dimethylethanethioamide
- Fimasartan D4
- 2-(2-Butyl-4-methyl-6-oxo-1-{[2'-(1H-tetrazol-5-yl)-4-biphenylyl] methyl}-1,6-dihydro-5-pyrimidinyl)-N,N-dimethylethanethioamide (Fimasartan)
- 2-(1-((2'-(2H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide
- 2-(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide
- 2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one
- 5-Pyrimidineethanethioamide, 2-butyl-1,6-dihydro-N,N,4-trimethyl-6-oxo-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- 247257-48-3
- C27H31N7OS
- Inhibitors
- API
